YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway
Open Access
- 1 January 2019
- journal article
- research article
- Published by Taylor & Francis Ltd in Drug Design, Development and Therapy
- Vol. ume 13, 317-326
- https://doi.org/10.2147/dddt.s185514
Abstract
Background: Y-box-binding protein-1 (YB-1) is aberrantly expressed in a variety of cancers. However, the biological functional role of YB-1 in glioma is not yet clear. Methods: The expression of MDM2 and YB-1 was analyzed by real time PCR. Overexpression and knockdown of YB-1 in glioma cells were created by transfection of pcDNA-YB-1 and siRNA against YB-1, respectively. Cell viability was performed by CCK8 assay. Results: Our findings showed that glioma tissues had higher expressions of YB-1 than that in cancer-free tissues in 54 glioma patients, which were also positively correlated with Murine MDM2 expression. Overexpression of YB-1 or MDM2 renders a drug resistance feature in glioma cell exposed to temozolomide (TMZ), by directly targeting p53. Genetic or chemical inhibition of MDM2 significantly blocked YB-1-modulated response of glioma cells to TMZ. Moreover, inhibition of YB-1 or MDM2 reduced glioma cells metastasis and mortality in mice. Conclusion: YB-1 facilitates the resistance of glioma cells to TMZ by direct activation of MDM2/p53 signaling and represents a promising molecular target for glioma treatment.Keywords
This publication has 35 references indexed in Scilit:
- YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cellsJournal of Translational Medicine, 2013
- Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activitiesCell Communication and Signaling, 2013
- Cancer as an immune-mediated diseaseImmunoTargets and Therapy, 2012
- Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma MultiformePLOS ONE, 2011
- Y-Box Binding Protein-1 Induces the Expression of CD44 and CD49f Leading to Enhanced Self-Renewal, Mammosphere Growth, and Drug ResistanceCancer Research, 2010
- Emerging roles of E2Fs in cancer: an exit from cell cycle controlNature Reviews Cancer, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer TherapyAnnual Review of Pharmacology and Toxicology, 2009
- Y-box-binding protein 1 confers EGF independence to human mammary epithelial cellsOncogene, 2005
- The pleiotropic functions of the Y‐box‐binding protein, YB‐1BioEssays, 2003